Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.

Nakazawa Y, Nakazawa S, Kurozumi S, Ogino M, Koibuchi Y, Odawara H, Oyama T, Horiguchi J, Fujii T, Shirabe K.

Oncol Lett. 2020 Apr;19(4):2705-2712. doi: 10.3892/ol.2020.11354. Epub 2020 Jan 27.

2.

Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer.

Fujii T, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Shirabe K.

In Vivo. 2020 Mar-Apr;34(2):917-921. doi: 10.21873/invivo.11858.

PMID:
32111804
3.

RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis.

Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, Moriya S, Idichi T, Maemura K, Fujii T, Horiguchi J, Kijima Y, Natsugoe S.

Mol Oncol. 2020 Feb;14(2):426-446. doi: 10.1002/1878-0261.12602. Epub 2019 Dec 29.

4.

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K.

Sci Rep. 2019 Nov 13;9(1):16662. doi: 10.1038/s41598-019-52944-6.

5.

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

Kurozumi S, Alsaeed S, Orah N, Miligy IM, Joseph C, Aljohani A, Toss MS, Fujii T, Shirabe K, Green AR, Aleskandarany MA, Rakha EA.

Breast Cancer Res Treat. 2020 Feb;179(3):557-564. doi: 10.1007/s10549-019-05488-2. Epub 2019 Nov 9.

PMID:
31707510
6.

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.

Kariri YA, Joseph C, Kurozumi S, Toss MS, Alsaleem M, Raafat S, Mongan NP, Aleskandarany MA, Green AR, Rakha EA.

Breast Cancer Res Treat. 2020 Jan;179(2):349-357. doi: 10.1007/s10549-019-05466-8. Epub 2019 Nov 2.

7.

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2020 Jan;179(1):79-90. doi: 10.1007/s10549-019-05459-7. Epub 2019 Oct 10.

8.

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Joseph C, Al-Izzi S, Alsaleem M, Kurozumi S, Toss MS, Arshad M, Goh FQ, Alshankyty IM, Aleskandarany MA, Ali S, Ellis IO, Mongan NP, Green AR, Rakha EA.

Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.

PMID:
31558802
9.

A novel hydrochloride-free chitosan oligosaccharide production method to improve taste.

Kurozumi S, Kiyose M, Noguchi T, Sato K.

Int J Biol Macromol. 2019 Nov 1;140:109-118. doi: 10.1016/j.ijbiomac.2019.08.067. Epub 2019 Aug 8.

PMID:
31401284
10.

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.

Kurozumi S, Kaira K, Matsumoto H, Hirakata T, Yokobori T, Inoue K, Horiguchi J, Katayama A, Koshi H, Shimizu A, Oyama T, Sloan EK, Kurosumi M, Fujii T, Shirabe K.

Breast Cancer Res Treat. 2019 Oct;177(3):603-610. doi: 10.1007/s10549-019-05341-6. Epub 2019 Jul 9.

PMID:
31290053
11.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
12.

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.

Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi SI, Fujii T, Horiguchi J, Shirabe K, Inoue K.

PLoS One. 2019 May 21;14(5):e0217279. doi: 10.1371/journal.pone.0217279. eCollection 2019.

13.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
14.

Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis.

Kurozumi S, Matsumoto H, Kurosumi M, Inoue K, Fujii T, Horiguchi J, Shirabe K, Oyama T, Kuwano H.

Oncol Lett. 2019 Mar;17(3):2647-2656. doi: 10.3892/ol.2019.9938. Epub 2019 Jan 16.

15.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.

PMID:
30760857
16.

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.

Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K.

Sci Rep. 2019 Feb 7;9(1):1583. doi: 10.1038/s41598-018-38272-1.

17.

Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.

Handa T, Katayama A, Yokobori T, Yamane A, Fujii T, Obayashi S, Kurozumi S, Kawabata-Iwakawa R, Gombodorj N, Nishiyama M, Asao T, Shirabe K, Kuwano H, Oyama T.

Int J Oncol. 2019 Mar;54(3):833-844. doi: 10.3892/ijo.2019.4675. Epub 2019 Jan 4.

18.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

19.

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.

Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K.

Med Mol Morphol. 2019 Jun;52(2):90-98. doi: 10.1007/s00795-018-0206-y. Epub 2018 Sep 27.

PMID:
30259117
20.

Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.

Toda H, Kurozumi S, Kijima Y, Idichi T, Shinden Y, Yamada Y, Arai T, Maemura K, Fujii T, Horiguchi J, Natsugoe S, Seki N.

J Hum Genet. 2018 Dec;63(12):1197-1210. doi: 10.1038/s10038-018-0510-3. Epub 2018 Sep 18.

PMID:
30228364
21.

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.

Kurozumi S, Matsumoto H, Inoue K, Tozuka K, Hayashi Y, Kurosumi M, Oyama T, Fujii T, Horiguchi J, Kuwano H.

PLoS One. 2018 Aug 6;13(8):e0201846. doi: 10.1371/journal.pone.0201846. eCollection 2018.

22.

Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.

Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Shirabe K.

Anticancer Res. 2018 Aug;38(8):4927-4931. doi: 10.21873/anticanres.12809.

PMID:
30061271
23.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
24.

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.

Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M.

Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3.

PMID:
29971625
25.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

26.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
27.

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.

Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H.

Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21. Review.

PMID:
28936553
28.

Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.

Fujii T, Yanai K, Tokuda S, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Hirakata T, Kuwano H.

Anticancer Res. 2017 Sep;37(9):5053-5056.

PMID:
28870933
29.

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.

Kurozumi S, Matsumoto H, Hayashi Y, Tozuka K, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M.

BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.

30.

Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.

Fujii T, Yajima R, Kurozumi S, Higuchi T, Obayashi S, Tokiniwa H, Nagaoka R, Takata D, Horiguchi J, Kuwano H.

Anticancer Res. 2016 Oct;36(10):5481-5485.

PMID:
27798919
31.

Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J.

J Hum Genet. 2017 Jan;62(1):15-24. doi: 10.1038/jhg.2016.89. Epub 2016 Jul 21. Review.

PMID:
27439682
32.

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.

Kurozumi S, Yamaguchi Y, Hayashi S, Hiyoshi H, Suda T, Gohno T, Matsumoto H, Takei H, Horiguchi J, Takeyoshi I, Oyama T, Kurosumi M.

Cancer Med. 2016 Aug;5(8):1873-82. doi: 10.1002/cam4.780. Epub 2016 Jun 23.

33.

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, Takeyoshi I, Oyama T, Ranger-Moore J, Allred DC, Dennis E, Nitta H.

Breast Cancer Res Treat. 2016 Jul;158(1):99-111. doi: 10.1007/s10549-016-3856-2. Epub 2016 Jun 18.

35.

Metabolomic Analysis of Blood Plasma after Oral Administration of N-acetyl-d-Glucosamine in Dogs.

Osaki T, Kurozumi S, Sato K, Terashi T, Azuma K, Murahata Y, Tsuka T, Ito N, Imagawa T, Minami S, Okamoto Y.

Mar Drugs. 2015 Aug 7;13(8):5007-15. doi: 10.3390/md13085007.

36.

Anti-inflammatory effects of orally administered glucosamine oligomer in an experimental model of inflammatory bowel disease.

Azuma K, Osaki T, Kurozumi S, Kiyose M, Tsuka T, Murahata Y, Imagawa T, Itoh N, Minami S, Sato K, Okamoto Y.

Carbohydr Polym. 2015 Jan 22;115:448-56. doi: 10.1016/j.carbpol.2014.09.012. Epub 2014 Sep 21.

PMID:
25439918
37.

Anti-tumor properties of orally administered glucosamine and N-acetyl-D-glucosamine oligomers in a mouse model.

Masuda S, Azuma K, Kurozumi S, Kiyose M, Osaki T, Tsuka T, Itoh N, Imagawa T, Minami S, Sato K, Okamoto Y.

Carbohydr Polym. 2014 Oct 13;111:783-7. doi: 10.1016/j.carbpol.2014.04.102. Epub 2014 May 10.

PMID:
25037416
38.

Evaluation of the effects of chitin nanofibrils on skin function using skin models.

Ito I, Osaki T, Ifuku S, Saimoto H, Takamori Y, Kurozumi S, Imagawa T, Azuma K, Tsuka T, Okamoto Y, Minami S.

Carbohydr Polym. 2014 Jan 30;101:464-70. doi: 10.1016/j.carbpol.2013.09.074. Epub 2013 Oct 1.

PMID:
24299799
39.

Metabolomic analyses of blood plasma after oral administration of D-glucosamine hydrochloride to dogs.

Osaki T, Azuma K, Kurozumi S, Takamori Y, Tsuka T, Imagawa T, Okamoto Y, Minami S.

Mar Drugs. 2012 Aug;10(8):1873-82. Epub 2012 Aug 22.

40.

Formation of a new crystalline form of anhydrous β-maltose by ethanol-mediated crystal transformation.

Verhoeven N, Neoh TL, Ohashi T, Furuta T, Kurozumi S, Yoshii H.

Carbohydr Res. 2012 Apr 1;351:74-80. doi: 10.1016/j.carres.2012.01.011. Epub 2012 Jan 28.

PMID:
22341504
41.

[A case of aromatase inhibitor-tolerant metastatic breast cancer revealing complete remission with high-dose toremifene therapy].

Kurozumi S, Takeo T, Ikeda F, Horiguchi J, Takeyoshi I, Ito H.

Gan To Kagaku Ryoho. 2011 Jan;38(1):93-6. Japanese.

PMID:
21368465
42.

[Chitin/cisplatin--an adhesive anticancer drug].

Sugitachi A, Otsuka K, Itabashi T, Chiba T, Kimura Y, Sasaki A, Ikeda K, Uesugi N, Takamori Y, Kurozumi S, Mori T, Wakabayashi G.

Gan To Kagaku Ryoho. 2008 Nov;35(12):2021-3. Japanese.

PMID:
19106510
43.

[A novel anticancer drug delivery system -DAC-70/CDDP].

Sugitachi A, Otsuka K, Fujisawa K, Itabashi T, Akiyama Y, Sasaki A, Ikeda K, Yoshida Y, Takamori Y, Kurozumi S, Mori T, Wakabayashi G.

Gan To Kagaku Ryoho. 2007 Nov;34(12):2159-61. Japanese.

PMID:
18219931
44.

[Study on aspiration and swallowing exercise in stroke patients].

Maeshima S, Osawa A, Takajo F, Kurozumi S, Ota N, Kumakura I.

Brain Nerve. 2007 Sep;59(9):977-81. Japanese.

PMID:
17886480
45.

[A comparison study of aspiration with clinical manifestions in stroke patients].

Maeshima S, Osawa A, Takajo F, Kurozumi S, Ota N, Kumakura I.

Brain Nerve. 2007 May;59(5):521-6. Japanese.

PMID:
17533978
46.

[A novel approach to loco-regional cancer chemotherapy with a chitosan-CDDP solution].

Otsuka K, Akiyama Y, Itabashi T, Sasaki A, Ikeda K, Takamori Y, Kurozumi S, Wakabayashi G.

Gan To Kagaku Ryoho. 2006 Nov;33(12):1866-8. Japanese.

PMID:
17212130
47.

A sensitive gait parameter for quantification of arthritis in rats.

Orito K, Kurozumi S, Ishii I, Tanaka A, Sawada J, Matsuda H.

J Pharmacol Sci. 2007 Jan;103(1):113-6. Epub 2007 Jan 1.

48.

Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-deoxy-Delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826).

Fukushima S, Takeuchi Y, Kishimoto S, Yamashita S, Uetsuki K, Shirakawa S, Suzuki M, Furuta K, Noyori R, Sasaki H, Kikuchi Y, Kita T, Yamori T, Sawada J, Kojima M, Hazato A, Kurozumi S, Fukushima M.

Anticancer Drugs. 2001 Mar;12(3):221-34.

PMID:
11290870
49.
50.

[Pharmaceutical and pharmacological development of antitumor prostaglandins].

Fukushima S, Kishimoto S, Takeuchi Y, Fukushima M, Suzuki M, Furuta K, Noyori R, Sasaki H, Kikuchi Y, Nakano M, Kurozumi S.

Nihon Rinsho. 1998 Mar;56(3):663-9. Review. Japanese.

PMID:
9549353

Supplemental Content

Loading ...
Support Center